SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
GTX Corp Submits Clinical Hold Complete Response Letter to FDA For Its Planned Phase II Clinical Study Of Capesaris® For Secondary Hormonal Therapy of Advanced Prostate Cancer